![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell...
PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials – – Initial...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01 | 13.3333333333 | 0.075 | 0.085 | 0.075 | 3336 | 0.075 | CS |
4 | -0.005 | -5.55555555556 | 0.09 | 0.09 | 0.075 | 4841 | 0.0806669 | CS |
12 | -0.015 | -15 | 0.1 | 0.135 | 0.07 | 8611 | 0.10607371 | CS |
26 | 0.015 | 21.4285714286 | 0.07 | 0.135 | 0.06 | 9177 | 0.09222075 | CS |
52 | 0.01 | 13.3333333333 | 0.075 | 0.135 | 0.06 | 9732 | 0.08114739 | CS |
156 | -0.045 | -34.6153846154 | 0.13 | 0.15 | 0.01 | 84367 | 0.03670475 | CS |
260 | -0.055 | -39.2857142857 | 0.14 | 0.17 | 0.01 | 119487 | 0.0805502 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions